Streetbeat News

Stock Prices

JPM

Deep-pocketed investors are showing a bearish sentiment towards JPMorgan Chase (NYSE:JPM) with 70% of options activity being bearish. The options activity is unusually high, indicating potential significant market movements. Analysts have mixed ratings, with Morgan Stanley maintaining an Overweight rating and Deutsche Bank downgrading to Hold.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 4:32 pm

TYL

Tyler Technologies (NYSE:TYL) has significantly outperformed the market over the past 20 years, with an average annual return of 23.3%. A $100 investment in TYL 20 years ago would now be worth $6,726.97, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 4:30 pm

GDDY

GoDaddy (NYSE:GDDY) has outperformed the market over the past 5 years with an annualized return of 19.48%, resulting in a $100 investment growing to $240.24. This highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 4:30 pm

CRBP

Corbus Pharmaceuticals Holdings shares are trading lower in sympathy with Novo Nordisk after Novo's Phase2a trial results for Monlunabant in obesity. Wedbush maintained an Outperform rating on Corbus but lowered its price target from $85 to $51.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:29 pm

NKE

Nike's stock rally has stalled at the $88.50 resistance level, a former support level from April. This resistance is due to regretful buyers who bought at previous support levels and are now selling at breakeven. The stock's movement is influenced by trader psychology, with similar patterns observed at the $97.50 level.

Portfolio Pulse from Mark Putrino

September 20, 2024 | 4:27 pm

ELAN

Elanco Animal Health's shares are declining following a William Blair analyst's concerns about the efficacy and label warnings of its dermatology treatment for itchy dogs.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:26 pm

NVO

Novo Nordisk's stock declined after announcing results from a phase 2a trial of monlunabant, a drug for obesity. The trial showed significant weight loss but also mild to moderate side effects. Novo Nordisk plans a larger phase 2b trial in 2025. Additionally, Novo Nordisk entered a partnership with NanoVation Therapeutics for genetic medicines.

Portfolio Pulse from Vandana Singh

September 20, 2024 | 4:24 pm

NOW

ServiceNow (NYSE:NOW) has seen significant bearish options trading activity, with 40% of traders showing bearish tendencies. The stock is currently trading at $919.06, slightly down by 0.02%. An analyst from Needham downgraded its rating to Buy with a price target of $900. The anticipated earnings release is in 33 days.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 4:17 pm

AMAT

Whales are showing a bearish stance on Applied Materials (NASDAQ:AMAT) through options trading, with 40% of trades being bearish. The price range targeted is $140 to $210. Analysts have mixed ratings, with target prices ranging from $185 to $217.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 4:16 pm

GLE

The trading halt for an IPO security has been updated, and it is now released for quotation as of 12:15 PM ET.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:15 pm